71 related articles for article (PubMed ID: 12396608)
1. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies.
O'Connor DH; Allen TM; Watkins DI
DNA Cell Biol; 2002 Sep; 21(9):659-64. PubMed ID: 12396608
[TBL] [Abstract][Full Text] [Related]
2. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
3. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
4. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
Allen TM; O'Connor DH; Jing P; Dzuris JL; Mothé BR; Vogel TU; Dunphy E; Liebl ME; Emerson C; Wilson N; Kunstman KJ; Wang X; Allison DB; Hughes AL; Desrosiers RC; Altman JD; Wolinsky SM; Sette A; Watkins DI
Nature; 2000 Sep; 407(6802):386-90. PubMed ID: 11014195
[TBL] [Abstract][Full Text] [Related]
5. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
[TBL] [Abstract][Full Text] [Related]
6. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
Hanke T; Samuel RV; Blanchard TJ; Neumann VC; Allen TM; Boyson JE; Sharpe SA; Cook N; Smith GL; Watkins DI; Cranage MP; McMichael AJ
J Virol; 1999 Sep; 73(9):7524-32. PubMed ID: 10438842
[TBL] [Abstract][Full Text] [Related]
7. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection.
O'Connor D; Friedrich T; Hughes A; Allen TM; Watkins D
Immunol Rev; 2001 Oct; 183():115-26. PubMed ID: 11782252
[TBL] [Abstract][Full Text] [Related]
8. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
[TBL] [Abstract][Full Text] [Related]
9. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
[TBL] [Abstract][Full Text] [Related]
10. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
[TBL] [Abstract][Full Text] [Related]
12. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.
O'Connor DH; Allen TM; Vogel TU; Jing P; DeSouza IP; Dodds E; Dunphy EJ; Melsaether C; Mothé B; Yamamoto H; Horton H; Wilson N; Hughes AL; Watkins DI
Nat Med; 2002 May; 8(5):493-9. PubMed ID: 11984594
[TBL] [Abstract][Full Text] [Related]
13. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys.
Barouch DH; Kunstman J; Glowczwskie J; Kunstman KJ; Egan MA; Peyerl FW; Santra S; Kuroda MJ; Schmitz JE; Beaudry K; Krivulka GR; Lifton MA; Gorgone DA; Wolinsky SM; Letvin NL
J Virol; 2003 Jul; 77(13):7367-75. PubMed ID: 12805435
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
[TBL] [Abstract][Full Text] [Related]
15. Reversion of CTL escape-variant immunodeficiency viruses in vivo.
Friedrich TC; Dodds EJ; Yant LJ; Vojnov L; Rudersdorf R; Cullen C; Evans DT; Desrosiers RC; Mothé BR; Sidney J; Sette A; Kunstman K; Wolinsky S; Piatak M; Lifson J; Hughes AL; Wilson N; O'Connor DH; Watkins DI
Nat Med; 2004 Mar; 10(3):275-81. PubMed ID: 14966520
[TBL] [Abstract][Full Text] [Related]
16. AIDS. Escape from the immune system.
Walker BD; Goulder PJ
Nature; 2000 Sep; 407(6802):313-4. PubMed ID: 11014174
[No Abstract] [Full Text] [Related]
17. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.
Kawada M; Tsukamoto T; Yamamoto H; Takeda A; Igarashi H; Watkins DI; Matano T
J Virol; 2007 May; 81(10):5202-11. PubMed ID: 17344296
[TBL] [Abstract][Full Text] [Related]
18. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.
Allen TM; Mortara L; Mothé BR; Liebl M; Jing P; Calore B; Piekarczyk M; Ruddersdorf R; O'Connor DH; Wang X; Wang C; Allison DB; Altman JD; Sette A; Desrosiers RC; Sutter G; Watkins DI
J Virol; 2002 Apr; 76(8):4108-12. PubMed ID: 11907251
[TBL] [Abstract][Full Text] [Related]
19. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview.
Girard M; Habel A; Chanel C
C R Acad Sci III; 1999 Nov; 322(11):959-66. PubMed ID: 10646090
[TBL] [Abstract][Full Text] [Related]
20. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
Nixon DF; Donahoe SM; Kakimoto WM; Samuel RV; Metzner KJ; Gettie A; Hanke T; Marx PA; Connor RI
Virology; 2000 Jan; 266(1):203-10. PubMed ID: 10612675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
